Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin

Journal of Medical Virology

Volumn 82, Issue 5, 2010, Pages 747-754

  Levast, Marion ^a,b   Larrat, Sylvie ^a,c   Thelu, Marie Ange ^a,d,e   Nicod, Sandrine ^a   Plages, Agnès ^a   Cheveau, Alice ^a   Zarski, Jean Pierre ^a,d,e   Seigneurin, Jean Marie ^a   Morand, Patrice ^a,c   Leroy, Vincent ^a,d,e  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b Chambery Hospital   (France)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

^d INSERM   (France)

^e UNIV GRENOBLE ALPES   (France)

Author keywords

Alpha interferon; Hepatitis C; Occult HBV infection; Real time PCR; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASSAY; CHRONIC HEPATITIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; LIVER; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; SERUM; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS HEPATITIS; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BLOOD; DNA, VIRAL; FEMALE; FRANCE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; PREVALENCE; REAGENT KITS, DIAGNOSTIC; RIBAVIRIN;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 77950985533     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21695     Document Type: Article

References (44)

1. Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K. 2008. Impact of occult hepatitis Bvirus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol 43:849-856.
2. Allice T, Cerutti F, Pittaluga F, Varetto S, Gabella S, Marzano A, Franchello A, Colucci G, Ghisetti V. 2007. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: A novel automated real-time PCR assay for quantification of HBV DNA in plasma. J Clin Microbiol 45:828-834.
3. Awerkiew S, Daumer M, Reiser M, Wend UC, Pfister H, Kaiser R, Willems WR, Gerlich WH. 2007. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 38:83-86.
4. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. 1999. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341:22-26.
5. Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, Ascher NL, Wright TL. 1994. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 343:142-146.
6. Chemin I, Trepo C. 2005. Clinical impact of occult HBV infections. J Clin Virol 34:S15-S21.
7. Chemin I, Jeantet D, Kay A, Trepo C. 2001. Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease. Antiviral Res 52:117-123.
8. Chen SY, Kao CF, Chen CM, Shih CM, Hsu MJ, Chao CH, Wang SH, You LR, Lee YH. 2003. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 278:591-607.
9. Chevaliez S, Bouvier-Alias M, Laperche S, Pawlotsky JM. 2008. Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 46:1716-1723.
10. De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, Van Thiel DH. 2000. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 95:3529-3536.
11. Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P, de Lalla F, Webster GJ, Dusheiko G. 2004. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 29:160-166.
12. Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, Kushiyama Y, Uchida Y, Ihihara S, Akagi S, Watanabe M, Kinoshita Y. 1999. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 58:201-207.
13. Fukuda R, Ishimura N, Hamamoto S, Moritani M, Uchida Y, Ishihara S, Akagi S, Watanabe M, Kinoshita Y. 2001. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol 63:220-227.
14. Giudice CL, Martinengo M, Pietrasanta P, Bocciardo L, Malavasi C, Rastelli S, Faraci M, Tripodi G. 2008. Occult hepatitis B virus infection: A case of reactivation in a patient receiving immunosuppressive treatment for allogeneic bone marrow transplantation. Blood Transfus 6:46-50.
15. Hochberger S, Althof D, Gallegos de Schrott R, Nachbaur N, Rock H, Leying H. 2006. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 35:373-380.
16. Hu KQ. 2002. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 9:243-257.
17. Kanbay M, Gur G, Akcay A, Selcuk H, Yilmaz U, Arslan H, Boyacioglu S, Ozdemir FN, Siagris D, Christofidou M, Triga K, Pagoni N, Theocharis GJ, Goumenos D, Lekkou A, Thomopoulos K, Tsamandas AC, Vlachojannis J, Labropoulou-Karatza C. 2006. Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients? Occult hepatitis B virus infection in hemodialysis patients with chronic HCV infection. Dig Dis Sci 51:1962-1966.
18. Kao JH, Chen PJ, Lai MY, Chen DS. 2002. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 40:4068-4071.
19. Kazemi-Shirazi L, Petermann D, Muller C. 2000. Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C. J Hepatol 33:785-790.
20. Khattab E, Chemin I, Vuillermoz I, Vieux C, Mrani S, Guillaud O, Trepo C, Zoulim F. 2005. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. J Clin Virol 33:150-157.
21. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP. 2004. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: Comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 99:271-279.
22. Lo YM, Lo ES, Mehal WZ, Sampietro M, Fiorelli G, Ronchi G, Tse CH, Fleming KA. 1993. Geographical variation in prevalence of hepatitis B virus DNA in HBsAg negative patients. J Clin Pathol 46:304-308.
23. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. 1991. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188.
24. Marcellin P, Giostra E, Martinot-Peignoux M, Loriot MA, Jaegle ML, Wolf P, Degott C, Degos F, Benhamou JP. 1991. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 100:1432-1434.
25. Mariscal LF, Rodriguez-Inigo E, Bartolome J, Castillo I, Ortiz-Movilla N, Navacerrada C, Pardo M, Perez-Mota A, Graus J, Carreno V. 2004. Hepatitis B infection of the liver in chronic hepatitis C without detectable hepatitis B virus DNA in serum. J Med Virol 73:177-186.
26. Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, Trabaud MA, Chevallier P, Chevallier M, Zoulim F, Trepo C. 2007. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol 79:1075-1081.
27. Mulrooney-Cousins PM, Michalak TI. 2007. Persistent occult hepatitis B virus infection: Experimental findings and clinical implications. World J Gastroenterol 13:5682-5686.
28. Nirei K, Kaneko M, Moriyama M, Arakawa Y. 2000. The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen. Intervirology 43:95-101.
29. Raimondo G, Balsano C, Craxi A, Farinati F, Levrero M, Mondelli M, Pollicino T, Squadrito G, Tiribelli C. 2000. Occult hepatitis B virus infection. Dig Liver Dis 32:822-826.
30. Raimondo G, Pollicino T, Cacciola I, Squadrito G. 2007. Occult hepatitis B virus infection. J Hepatol 46:160-170.
31. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. 2001. HCV genotype and "silent" HBV coinfection: Two main risk factors for a more severe liver disease. J Med Virol 64:350-355.
32. Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, Piai G, Stanzione M, Bruno M, Moggio G, Caprio N, Pasquale G, Del Vecchio Blanco C. 2008. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: A multicenter study. J Med Virol 80:1547-1553.
33. Sanchez-Quijano A, Jauregui JI, Leal M, Pineda JA, Castilla A, Abad MA, Civeira MP, Garcia de Pesquera F, Prieto J, Lissen E. 1993. Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. J Hepatol 17:288-293.
34. Schuttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. 2002. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 37:855-862.
35. Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. 2008. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 14:534-540.
36. Siagris D, Christofidou M, Triga K, Pagoni N, Theocharis GJ, Goumenos D, Lekkou A, Thomopoulos K, Tsamandas AC, Vlachojannis J, Labropoulou-Karatza C. 2006. Occult hepatitis B virus infection in hemodialysis patients with chronic HCV infection. J Nephrol 19:327-333.
37. Su FH, Chen JD, Cheng SH, Lin CH, Liu YH, Chu FY. 2007. Seroprevalence of Hepatitis-B infection amongst Taiwanese university students 18 years following the commencement of a national Hepatitis-B vaccination program. J Med Virol 79:138-143.
38. Tamori A, Hayashi T, Shinzaki M, Kobayashi S, Iwai S, Enomoto M, Morikawa H, Sakaguchi H, Shiomi S, Takemura S, Kubo S, Kawada N. 2009. Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. J Med Virol 81:1009-1014.
39. Torbenson M, Thomas DL. 2002. Occult hepatitis B. Lancet Infect Dis 2:479-486.
40. Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. 2004. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 39:51-57.
41. Toyoda H, Hayashi K, Murakami Y, Honda T, Katano Y, Nakano I, Goto H, Kumada T, Takamatsu J. 2004. Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. J Med Virol 73:195-199.
42. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer JS, Roberts JP, Tomlanovich SJ, Vincenti F, Stock P. 1995. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 59:230-234.
43. Zaaijer HL, Torres P, Ontanon A, Ponte LG, Koppelman MH, Lelie PN, Hemert FJ, Boot HJ. 2008. Multiple surface antigen mutations in five blood donors with occult hepatitis B virus infection. J Med Virol 80:1344-1349.
44. Zuckerman JN, Zuckerman AJ. 2003. Mutations of the surface protein of hepatitis B virus. Antiviral Res 60:75-78.